Antiviral-HIV (Antiretroviral) Nonnucleoside RT Inhibitor

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells

They function through non-competitive, allosteric binding to an allosteric pocket adjacent to the active catalytic site of the HIV-1 reverse transcriptase enzyme

They function through non-competitive, allosteric binding to an allosteric pocket adjacent to the active catalytic site of the HIV-1 reverse transcriptase enzyme Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function

This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells

This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function

Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function